IDEAYA Biosciences, Inc. (IDYA)
NASDAQ: IDYA · Real-Time Price · USD
34.68
+0.37 (1.08%)
At close: Mar 4, 2026, 4:00 PM EST
35.20
+0.52 (1.50%)
Pre-market: Mar 5, 2026, 4:08 AM EST
IDEAYA Biosciences Stock Forecast
Stock Price Forecast
The 14 analysts with 12-month price forecasts for IDEAYA Biosciences stock have an average target of 51.21, with a low estimate of 30 and a high estimate of 79. The average target predicts an increase of 47.66% from the current stock price of 34.68.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for IDEAYA Biosciences stock from 16 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Sep '25 | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 4 | 4 | 4 | 5 | 6 |
| Buy | 11 | 11 | 9 | 9 | 8 | 9 |
| Hold | 1 | 2 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 15 | 17 | 14 | 14 | 14 | 16 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Citigroup | Citigroup | Strong Buy Maintains $64 → $65 | Strong Buy | Maintains | $64 → $65 | +87.43% | Feb 19, 2026 |
| RBC Capital | RBC Capital | Buy Reiterates $49 | Buy | Reiterates | $49 | +41.29% | Feb 18, 2026 |
| Guggenheim | Guggenheim | Strong Buy Reiterates $50 | Strong Buy | Reiterates | $50 | +44.18% | Feb 18, 2026 |
| Wedbush | Wedbush | Buy Maintains $49 → $52 | Buy | Maintains | $49 → $52 | +49.94% | Feb 18, 2026 |
| RBC Capital | RBC Capital | Buy Maintains $41 → $45 | Buy | Maintains | $41 → $45 | +29.76% | Jan 21, 2026 |
Financial Forecast
Revenue This Year
52.68M
from 218.71M
Decreased by -75.91%
Revenue Next Year
104.08M
from 52.68M
Increased by 97.58%
EPS This Year
-3.66
from -1.28
EPS Next Year
-3.59
from -3.66
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 176.4M | 180.3M | |||
| Avg | 52.7M | 104.1M | |||
| Low | n/a | 55.3M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | -19.4% | 242.3% | |||
| Avg | -75.9% | 97.6% | |||
| Low | - | 5.0% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | -2.43 | -2.80 | |||
| Avg | -3.66 | -3.59 | |||
| Low | -4.54 | -4.41 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.